Categories Earnings, Health Care

Acasti Pharma (ACST): Q3 2020 Earnings Snapshot

— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.

— Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year.

— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.

— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.

— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.

— Cash and cash equivalents and marketable securities totaled CAD25.7 million as of December 31, 2019.

— ACST shares gained 0.69% immediately following the announcement.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Should investors worry about Micron’s (MU) weak Q4 results and guidance?

The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,

What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?

Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a

NKE Earnings: Highlights of Nike’s Q1 2023 results

Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top